Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004
Lynk Pharmaceuticals, an innovative clinical stage company, announced that it has dosed the first cohort […]
Lynk's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that the Phase II clinical trial of LNK01001 […]
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that it has recently completed phase I trials […]
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more